Zocor «Simvastatin»

side effects of zocor, generic zocor, what is zocor, cheap zocor, buy zocor, generic for zocor, buy zocor online, zocor 20 mg, zocor 40 mg, drug zocor, medication zocor, purchase zocor, order zocor, online zocor, price zocor, discount zocor, zocor alternatives.
-Homozygous Familial Hypercholesterolemia:
On the basis of the results of a controlled clinical study, the recommended dose of ZOCOR is 40 mg/day administered at night or 80 mg per day divided into 3 intakes: 20 mg, 20 mg and 40 mg at night. ZOCOR must be used in addition to other therapies lipid-lowering agents, for example the LDL Apheresis, or if such treatments are not available.
-Cardiovascular prevention:
In patients at high risk of coronary disease (with or without Hyperlipidemia), the usual dose of ZOCOR is 20-40 mg/day, administered in a single decision the evening. Drug treatment can be initiated at the same time as the regime and exercise. Dosage adjustments, if necessary, shall be performed as indicated above.
-Associated treatments:
. ZOCOR is effective alone or in combination with bile acid binders. ZOCOR scheduled decision-making is 2 hours before or 4 hours after administration of a chelator of bile acid.
. In patients taking Cyclosporine, of danazol, gemfibrozil, other fibrates (except Fenofibrate), in association with ZOCOR, ZOCOR dosage shall not exceed 10 mg/day. In patients taking amiodarone and verapamil in association with ZOCOR, ZOCOR dosage of should not exceed 20 mg/day (see guard and precautions and interactions)
ZOCOR 40 mg/day treatment, compared to a placebo was significantly (p = 0.0003) reduces the risk of total mortality in patients treated with simvastatin (12.9%, 1328 patients) compared to placebo (14.7%, 1507 patients); in connection with a reduction of 18% of coronary deaths, respectively of 5.7% (587 patients) versus 6.9% (707 patients); p = 0.0005 is a reduction of the absolute risk of 1.2%. The reduction of deaths of non-vascular origin was not statistically significant. ZOCOR has also reduced by 27% (p < 0.0001) the risk of major coronary events (combined test with infarction of the non-fatal myocardial or coronary death). ZOCOR reduced 30% (p < 0.0001) the need for coronary revascularization procedures (including aorto-coronary bypass surgery and angioplasty PTCA) and 16% (p = 0.006) devices and other revascularization interventions not coronary. ZOCOR has reduced by 25% (p < 0.0001) the risk of cerebral vascular accident (stroke) in relation to the reduction of 30% of the risk of ischemic stroke (p < 0.0001). In addition, in the subgroup of patients with diabetes, ZOCOR reduced 21% (p = 0,0293) the risk of developing macrovascular complications, including interventions of peripheral revascularization (surgery or angioplasty), limb amputations, or for leg ulcers. The proportional events rate reduction was consistent in each of the subgroups of patients studied including such non-coronary patients but with a pathology blood cerebrovascular or peripheral, men and women, elderly patients at the inclusion in the study of less than 70 years or those of more than 70 years, patients with high blood pressure or those not in not having, and in particular patients with a rate of LDL-cholesterol less than 1.16 g/L (3.0 mmol/L) for inclusion.
In study 4 S (Scandinavian Simvastatin Survival Study), the effect of the treatment by ZOCOR on total mortality was evaluated in 4444 coronary patients and having a basal total cholesterol of 2.12 3.09 g/l (5.5 to 8.0 mmol/L). In this multicenter, randomized double blind controlled versus placebo, patients with angina pectoris or a history of myocardial infarction (STEMI) have been treated by a regime, the usual treatments and by ZOCOR 20-40 mg/day (n = 2221) or placebo (n = 2223) on a median duration of follow-up of 5.4 years. ZOCOR reduces the risk of mortality by 30% (3.3% absolute risk reduction). The risk of coronary death was reduced by 42% (3.5% absolute risk reduction). In addition, ZOCOR decreased from 34% the risk of major coronary events (coronary death more myocardial infarction fatal non-validated in hospitalization and silent IDM). In addition, ZOCOR significantly reduced of 28% the risk of vascular events brain fatal and non-fatal (stroke and transient ischaemic). For non-cardiovascular mortality, no statistically significant difference was observed between the groups.

Zocor is a cholesterol- lowering medication prescribed to inhibit the production of cholesterol by the liver.

ZOCOR (simvastatin) is a lipid-lowering agent that is derived synthetically from a fermentation product of Aspergillus terreus. It reduces levels of "bad" cholesterol and triglycerides in the blood, while increasing levels of "good" cholesterol.